Pandion

Pandion Therapeutics Announces Pricing of Initial Public Offering

Retrieved on: 
Friday, July 17, 2020
Underwriting, Finance, Economy, Money, Initial public offering, Actuarial science, Pandion, Public offering

WATERTOWN, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune disease, today announced the pricing of its initial public offering of 7,500,000 shares of its common stock at a public offering price of $18.00 per share, for gross proceeds of $135.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Pandion.

Key Points: 
  • WATERTOWN, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune disease, today announced the pricing of its initial public offering of 7,500,000 shares of its common stock at a public offering price of $18.00 per share, for gross proceeds of $135.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Pandion.
  • In addition, Pandion has granted the underwriters an option for a period of 30 days to purchase up to 1,125,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions.
  • Goldman Sachs & Co. LLC, Morgan Stanley and SVB Leerink are acting as joint book-running managers for the offering.
  • Pandion Therapeutics is developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune diseases.

Pandion Therapeutics Announces Issuance of U.S. Patent for Bifunctional Molecules Derived from TALON™ Platform

Retrieved on: 
Tuesday, June 9, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Immunology, Autoimmunity, the TALON Drug Design Platform, Pandion

Pandion Therapeutics , a clinical-stage, privately held biotechnology company developing modular protein therapeutics for autoimmune diseases, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No.

Key Points: 
  • Pandion Therapeutics , a clinical-stage, privately held biotechnology company developing modular protein therapeutics for autoimmune diseases, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No.
  • The bifunctional molecules protected under this patent were developed using Pandions proprietary TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform that enables Pandion to create bifunctional product candidates designed to concentrate immune effector modulators within a target organ.
  • The issuance of this key patent strengthens our growing intellectual property portfolio and demonstrates our expertise in the field of bifunctional therapeutics for autoimmune disease, said Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics.
  • Pandion Therapeutics is developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune diseases.

REPEAT - MegumaGold Provides Update on Osprey Acquisition and Its Projects

Retrieved on: 
Tuesday, April 14, 2020
Osprey, Pandion

The Company continues its discussions with Osprey Gold Development Ltd. (Osprey Gold) regarding the proposed business combination transaction whereby the Company will acquire 100% of the issued and outstanding shares of Osprey Gold (the Proposed Transaction).

Key Points: 
  • The Company continues its discussions with Osprey Gold Development Ltd. (Osprey Gold) regarding the proposed business combination transaction whereby the Company will acquire 100% of the issued and outstanding shares of Osprey Gold (the Proposed Transaction).
  • The Company continues to advance targeting and permitting work in preparation for core drilling activities on its Touquoy West Property.
  • As a result, MegumaGold has assembled a strategically positioned, district-scale tenure position of 108,589 hectares within the Meguma Gold District.
  • MegumaGold disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

MegumaGold Provides Update on Osprey Acquisition and Its Projects

Retrieved on: 
Tuesday, April 14, 2020
Osprey, Pandion

The Company continues its discussions with Osprey Gold Development Ltd. (Osprey Gold) regarding the proposed business combination transaction whereby the Company will acquire 100% of the issued and outstanding shares of Osprey Gold (the Proposed Transaction).

Key Points: 
  • The Company continues its discussions with Osprey Gold Development Ltd. (Osprey Gold) regarding the proposed business combination transaction whereby the Company will acquire 100% of the issued and outstanding shares of Osprey Gold (the Proposed Transaction).
  • The Company continues to advance targeting and permitting work in preparation for core drilling activities on its Touquoy West Property.
  • As a result, MegumaGold has assembled a strategically positioned, district-scale tenure position of 108,589 hectares within the Meguma Gold District.
  • MegumaGold disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

Pandion and Astellas Announce Collaboration to Deliver Pancreas-Targeted Immunomodulators

Retrieved on: 
Thursday, October 31, 2019
Biotechnology, Pharmaceutical, Health, Companies, Astellas Pharma, Mitsubishi UFJ Financial Group, Life sciences, Pandion, Industries, Pandion, Astellas

Pandion Therapeutics, Inc. (Pandion), and Astellas Pharma Inc. (TSE: 4503, "Astellas") announced today the signing of a License and Collaboration Agreement directed toward the research, development, and commercialization of locally acting immunomodulators for autoimmune diseases of the pancreas.

Key Points: 
  • Pandion Therapeutics, Inc. (Pandion), and Astellas Pharma Inc. (TSE: 4503, "Astellas") announced today the signing of a License and Collaboration Agreement directed toward the research, development, and commercialization of locally acting immunomodulators for autoimmune diseases of the pancreas.
  • Under the terms of the agreement, Pandion could receive up to $45 million as upfront and payments related to research and preclinical activities.
  • Additionally, if Astellas develops and commercializes multiple candidates for multiple pancreatic autoimmune diseases, Pandion is potentially eligible to receive more than $750 million in future development and commercial milestone payments from Astellas.
  • Pandion may also receive royalties on worldwide net sales of any commercial products developed through the collaboration.

Napatech A/S: Napatech Announces Agreement to Sell Pandion Network Recorder Product Line to CounterFlow AI

Retrieved on: 
Friday, November 2, 2018
Field-programmable gate array, Hardware acceleration, Pandion, Packet analyzer, Server, Computing, Greek mythology, Utility software

The Pandion network recording solution guarantees line-rate packet capture from 1 to 100 gigabits per second, with lossless write to disk.

Key Points: 
  • The Pandion network recording solution guarantees line-rate packet capture from 1 to 100 gigabits per second, with lossless write to disk.
  • Napatech launched Pandion in 2016 and has established a strong foothold in cybersecurity and network operations at a number of Fortune 100 companies.
  • The Pandion product line is powered by Napatech's FPGA-based SmartNIC software and hardware, enabling the network recorder's application software to scale to stunning performance metrics in low-cost, open and standard server platforms.
  • "This is a natural next step in our long relationship with the CounterFlow AI team," said Ray Smets, CEO of Napatech.